Genome-wide association scan reveals the landscape of inherited variability in response to warfarin dose

Genes determining the optimal dose of therapeutic warfarin have now been identified in a large-scale, genome-wide association scan

Genome-wide association scan reveals the landscape of inherited variability in response to warfarin dose

Genes determining the optimal dose of therapeutic warfarin have now been identified in a large-scale, genome-wide association scan (GWAS) of this pharmacogenetic trait. Researchers from the Wellcome Trust Sanger Institute, Uppsala University Hospital, and the Karolinska Institute have found common sequence variants in three genes - VKORC1, CYP2C9 and CYP4F2 - that explain over 40 per cent of the variability in the warfarin dose needed to achieve proper blood thinning. The study, published March 20 in the open-access journal PLoS Genetics, assayed more than 1000 warfarin patients at approximately 370,000 chromosomal variants densely covering the human genome.

Warfarin is a widely prescribed anticoagulant, administered to reduce the risk of stroke, deep vein thrombosis, pulmonary embolism and heart attack in high-risk patients. However, patients vary widely (20-fold) in the warfarin dose needed, meaning that initial doses in some patients are too high (risking severe bleeding) or too low (risking serious illness). Identification of genetic factors causing dose variation could now be used to more accurately forecast the required warfarin dose and thereby reduce patient risk.

The statistical techniques and large GWAS sample enabled detection of the minor effect of CYP4F2 (explaining ~1.5 per cent of the dose variability) and the major effects of VKORC1 (~30 per cent) and CYP2C9 (~12 per cent). Together, these results provide the first comprehensive overview of the genetic landscape influencing variability in warfarin dosage.

The study concludes that clinical trials of dose forecasting based on VKORC1 and CYP2C9 (with the possible inclusion of CYP4F2) are likely to provide state-of-the-art clinical benchmarks for warfarin use in the foreseeable future. Future studies could also expand the search to identify the genetic determinants of life-threatening bleeding, a rare adverse reaction to warfarin treatment.

Notes to Editors
Publications
  • A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

    Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N et al.

    PLoS genetics 2009;5;3;e1000433

Participating Centres
  • Wellcome Trust Sanger Institute, Hinxton, United Kingdom
  • Clinical Pharmacology, Karolinska Institute, Campus Huddinge, Stockholm, Sweden
  • Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options